Yahoo Finance

AB Science will participate in the Biomed Forum investors conference

AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by ...
Yahoo Finance

AB Science will publish its 2024 annual financial report on May 9, 2025

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...
Morningstar

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

AB Science SA (Euronext - FR0010557264 - AB) today announced the approval of the third of four stages of the Phase I/II study (AB18001) with the compound AB8939 in adult patients with ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
FierceBiotech

AB Science trumpets phase 3 ALS data, but investors seem unmoved

After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...
FierceBiotech

AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of Masitinib in the treatment of Pancreatic Cancer

(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), confirms the filing to EMA for the ...
Business Insider

AB Science today reports its revenues for the first half of 2025 and provides an update on its activities

AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Paris, October 10, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...
manilatimes

AB Science reports its revenues for the year 2024 and provides an update on its activities

Update on the AB8939 microtubule program and in particular on the ability of AB8939 to generate a response on MECOM rearrangement AB Science provided an update on the microtubule program AB8939.
Business Insider

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY ...
manilatimes

AB Science announces the successful completion of a EUR 1.925 million private placement

AB Science S.A. (the "Company” or "AB Science”, Euronext - FR0010557264 - AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by ...
Yahoo Finance

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating ...